Advertisement
Advertisement
U.S. Markets close in 2 hrs 23 mins
Advertisement
Advertisement
Advertisement
Advertisement

Erasca, Inc. (ERAS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.01+0.43 (+5.67%)
As of 01:33PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.58
Open7.57
Bid7.95 x 1000
Ask7.97 x 1000
Day's Range7.57 - 8.42
52 Week Range4.51 - 22.94
Volume423,948
Avg. Volume497,695
Market Cap971.213M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
  • GlobeNewswire

    Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022

    SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities Precision Oncology Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat

  • GlobeNewswire

    Erasca to Present at the Morgan Stanley Global Healthcare Conference

    SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley Global Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat at 12:55 pm Eastern

  • Benzinga

    Erasca Touts Promising Early Data From Lead Cancer Programs

    Erasca Inc (NASDAQ: ERAS) announced preliminary Phase 1/1b monotherapy data for ERAS-007 and ERAS-601 in solid tumor settings. A retrospective pooled analysis of all trials evaluating ERAS-007 or ERAS-601 in advanced solid tumors included Erasca's ongoing HERKULES-1 and FLAGSHP-1 trials and Asana BioSciences' previously completed ASN007-101 trial. Key findings from the retrospective pooled interim analysis of ERAS-007 and ERAS-601 show that 23% (6/26) of patients with RAS/MAPK-altered non-colore

Advertisement
Advertisement